Navigation Links
Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
Date:3/31/2009

-- New Claims Cover Phospholipid-Targeting Compounds Linked to Anti-Viral Agents --

TUSTIN, Calif., March 31 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported the issuance of a U.S. patent that further strengthens the company's intellectual property leadership in the field of phospholipid-targeting agents for the treatment of life-threatening diseases. The new patent grants composition of matter claims that cover multiple formulations of phosphatidylethanolamine (PE)-binding agents attached to a wide variety of anti-viral agents. PE belongs to the aminophospholipid family that also includes phosphatidylserine (PS), the target for Peregrine's monoclonal antibody bavituximab that is in a clinical trial for hepatitis C virus (HCV) infection and in preclinical studies for HIV and other viral infections. This new patent follows issuance last year of broad methods patents covering use of PE-binding agents in anti-viral applications.

"Our anti-viral program has gained momentum over the past year with prestigious scientific publications and presentations, as well as the award of a major federal contract to Peregrine for the development of our anti-PS antibodies for biodefense applications," said Steven W. King, president and CEO of Peregrine. "Our growing patent estate in the closely related field of anti-PE binding agents should provide us with additional scientific and strategic options for leveraging our promising anti-viral assets."

The science underlying Peregrine's patents for anti-viral applications of PE-targeting agents was presented at a scientific conference last year by Dr. Melina Soares of the University of Texas Southwestern Medical Center(1). Dr. Soares presented data showing that similar to PS, the aminophospholipid PE is normally located on t
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
2. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
3. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
4. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
5. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
6. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
7. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
8. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
9. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
10. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
11. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 The laboratory information management ... witnessed a number of technological advancements due to factors ... growing need to integrate healthcare systems, and increasing government ... in system integration. Key players in the market focus ...
(Date:1/22/2015)... California (PRWEB) January 22, 2015 Pipette.com ... Offer to their comprehensive portfolio of Eppendorf products. ... customers to purchase a Centrifuge 5424/5424 R and receive ... of either Eppendorf Research plus or Eppendorf Reference 2 ...
(Date:1/22/2015)... DE (PRWEB) January 22, 2015 Controlled ... Pistoia Alliance, which helps companies check the legal requirements ... to expand to China. , As their international ... are globally adopting software solutions built as a result ...
(Date:1/22/2015)... Nueva Jersey , 22 de enero de 2015 ... Research abre hoy su llamada a nominaciones para 2015. ... científica ha hecho, o tiene el potencial para hacer, ... Las nominaciones se aceptarán hasta el 15 de marzo ...
Breaking Biology Technology:Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Global Compliance Service for Controlled Substances to Expand to China 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... 25 Years of Life ... Sciences Industry Experience, RANCHO CORDOVA, Calif., Aug. ... innovative products that,process and store adult stem cells, said today that ... America, has been named to the Company,s Board of,Directors. Her appointment ...
... AEterna Zentaris Inc.,(NASDAQ: AEZS , TSX: AEZ), ... oncology, will announce its second quarter 2008,financial and ... 12,2008. The Company will host a conference call ... day at 4:30 p.m., Eastern Time., Participants ...
... $623 Million; GAAP EPS $0.53; Adjusted EPS $0.48, ... WPI ), a leading specialty pharmaceutical,company, today reported financial ... Second Quarter 2008 Results, Net revenue for the ... $60.3 million, or $0.53 per diluted share. Net income ...
Cached Biology Technology:ThermoGenesis Names Tiffany Olson to Board of Directors 2ThermoGenesis Names Tiffany Olson to Board of Directors 3Watson Pharmaceuticals Reports Second Quarter 2008 Results 2Watson Pharmaceuticals Reports Second Quarter 2008 Results 3Watson Pharmaceuticals Reports Second Quarter 2008 Results 4Watson Pharmaceuticals Reports Second Quarter 2008 Results 5Watson Pharmaceuticals Reports Second Quarter 2008 Results 6Watson Pharmaceuticals Reports Second Quarter 2008 Results 7Watson Pharmaceuticals Reports Second Quarter 2008 Results 8Watson Pharmaceuticals Reports Second Quarter 2008 Results 9Watson Pharmaceuticals Reports Second Quarter 2008 Results 10Watson Pharmaceuticals Reports Second Quarter 2008 Results 11Watson Pharmaceuticals Reports Second Quarter 2008 Results 12Watson Pharmaceuticals Reports Second Quarter 2008 Results 13Watson Pharmaceuticals Reports Second Quarter 2008 Results 14Watson Pharmaceuticals Reports Second Quarter 2008 Results 15Watson Pharmaceuticals Reports Second Quarter 2008 Results 16Watson Pharmaceuticals Reports Second Quarter 2008 Results 17
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading ... the launch of its new website design. "When ... its infancy", says Peter O,Neill , founder and CEO ... the industry needs involvement from the key players on a ...
(Date:1/22/2015)... 13, 2015 Technology Showcase, Hall E -   EyeLock ... today announced it will showcase its EyeLock ID technology integrated ... Department of Energy,s Oak Ridge National Laboratory (ORNL) ... EyeLock,s iris identity authentication technology is being used to validate ...
(Date:1/22/2015)... 2015  A man-made form of insulin delivered by nasal ... in adults with mild cognitive impairment and Alzheimer,s disease ... at Wake Forest Baptist Medical Center. The ... cognitive impairment (MCI) or mild to moderate Alzheimer,s dementia ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... were made whole again by bone tissue grown from ... defects (defects that would not otherwise heal on their ... forms the skull, is a vivid demonstration of new ... use hESCs for tissue regeneration. Using mesenchymal ...
... (December 1, 2007) Damaged or defective genes have ... cancers. Over the past decade, however, scientists have discovered ... off and can cause cancer without any changes in ... poorly understood. Researchers in the laboratory of ...
... Water chemistry and mineralogy are scientific fields that have ... technologies. The boundary of water and rock, however, is ... field of nanoparticle science. Scientists are discovering that ... and engineered water chemistry and systems differently than similar ...
Cached Biology News:Human embryonic stem cell -- derived bone tissue closes massive skull injury 2DNA methylation shown to promote development of colon tumors 2DNA methylation shown to promote development of colon tumors 3Between water and rock -- a new science 2Between water and rock -- a new science 3Between water and rock -- a new science 4Between water and rock -- a new science 5
...
... siSolutions siRNA Custom Synthesis Service ... duplex RNA to knockdown any ... (19 RNA base pairs with ... 27-mers, or other lengths of ...
... to CRF The antibody ... CRF sequence that it was ... are found in the paraventricular ... in colchicine treated 4% FA ...
...
Biology Products: